US equities |
TSLA $391.62 ▲+5.21% MU $903.70 ▲+2.98% NVDA $216.00 ▲+2.39% META $630.56 ▼-1.88% SPCX $146.90 ▼-0.40% AAPL $343.91 ▼-1.10% MSFT $532.60 ▲+1.54% INTC $90.47 ▲+4.04%
FinancialContent

Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

2.290 +2.010 (+717.86%)
Delayed Quote Updated: 3:59 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Propanc Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability
Peer-Reviewed Scientific Reports Data & Academic Collaboration Show Potent Anti-Tumor Activity, EMT Reversal, & Sequential Chemo-Sensitization; Phase 1b First-In-Human Study Planned for Q1 2027 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
Scientific Reports Paper Shows Synergistic Trypsinogen/Chymotrypsinogen A Combination (1:6) Inhibits Angiogenesis, Migration, Invasion and EMT While Delivering Significant Tumor Reduction in Orthotopic... 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE... 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to... 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia 
From Propanc Biopharma, Inc.
Via GlobeNewswire
Friday's session: top gainers and losers ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-08-27: top gainers and losers in today's session. ↗
Via Chartmill
These stocks are the most active in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million. Propanc Biopharma (NASDAQ:PPCB) stock... 
Via Benzinga
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
Contrasting Science with Revolution Medicines and Erasca 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
Accelerates Phase 1b First-in-Human Trial Timeline 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
Purchasing $500,000 within First 30 days Since Program Commencement 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
A Promising Strategy for Improving Production for Applications in Biotechnology Research 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP 
From Propanc Biopharma, Inc.
Via GlobeNewswire
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period 
From Propanc Biopharma, Inc.
Via GlobeNewswire
News headline image
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
Pre-production, Engineering Run and GMP Manufacture of PRP in 2026 
From Propanc Biopharma, Inc.
Via GlobeNewswire
These stocks that are showing activity before the opening bell on Friday. ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-06-11: top gainers and losers in today's session. ↗
Via Chartmill
These stocks are the most active in today's session ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors 
From Propanc Biopharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >